DNLI FY2025 EPS Forecast Lowered by Cantor Fitzgerald

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Investment analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for shares of Denali Therapeutics in a report released on Thursday, April 10th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will post earnings per share of ($3.04) for the year, down from their prior estimate of ($3.00). Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.08.

Several other brokerages also recently weighed in on DNLI. The Goldman Sachs Group dropped their target price on shares of Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating for the company in a report on Tuesday, January 28th. JPMorgan Chase & Co. decreased their target price on shares of Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating on the stock in a research report on Tuesday, January 7th. Deutsche Bank Aktiengesellschaft began coverage on shares of Denali Therapeutics in a report on Tuesday, February 11th. They set a "buy" rating and a $31.00 price target on the stock. William Blair restated an "outperform" rating on shares of Denali Therapeutics in a report on Friday, February 28th. Finally, Oppenheimer lowered their target price on shares of Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating for the company in a research note on Monday, March 3rd. One research analyst has rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Denali Therapeutics currently has a consensus rating of "Buy" and an average target price of $37.57.

Remove Ads

Denali Therapeutics Trading Down 0.8 %

NASDAQ DNLI traded down $0.10 on Monday, hitting $13.17. 1,111,450 shares of the company traded hands, compared to its average volume of 1,081,883. Denali Therapeutics has a 52-week low of $10.57 and a 52-week high of $33.33. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of -4.77 and a beta of 1.58. The business's 50 day moving average price is $16.14 and its 200-day moving average price is $21.60.

Hedge Funds Weigh In On Denali Therapeutics

Several hedge funds have recently made changes to their positions in DNLI. KLP Kapitalforvaltning AS purchased a new position in shares of Denali Therapeutics during the fourth quarter worth $532,000. Proficio Capital Partners LLC acquired a new stake in Denali Therapeutics in the 4th quarter worth about $514,000. JPMorgan Chase & Co. raised its stake in Denali Therapeutics by 6.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company's stock valued at $6,857,000 after purchasing an additional 14,324 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of Denali Therapeutics by 13.8% in the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company's stock valued at $36,076,000 after buying an additional 149,939 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Denali Therapeutics by 7.6% in the fourth quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company's stock valued at $244,993,000 after purchasing an additional 843,996 shares in the last quarter. 92.92% of the stock is owned by institutional investors and hedge funds.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.